2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab
Badar T, Szabo A, Advani A, Wadleigh M, Arslan S, Khan MA, Aldoss I, Siebenaller C, Schultz E, Hefazi M, Shallis RM, Yurkiewicz I, Podoltsev N, Patel AA, Curran E, Balasubramanian S, Yang J, Mattison RJ, Burkart M, Dinner S, Liedtke M, Litzow MR, Atallah E. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Advances 2020, 4: 2308-2316. PMID: 32453836, PMCID: PMC7252553, DOI: 10.1182/bloodadvances.2019001381.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntibodies, BispecificB-LymphocytesHumansMiddle AgedPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-LymphomaRetrospective StudiesYoung AdultConceptsMedian relapse-free survivalAllogeneic hematopoietic cell transplantationHematopoietic cell transplantationRelapse-free survivalAcute lymphoblastic leukemiaOverall survivalCell transplantationRR diseaseClinical trialsComplete remission/complete remissionRetrospective multicenter cohort analysisB-cell acute lymphoblastic leukemiaB-cell acute lymphocytic leukemia patientsCytokine release syndromeIncomplete count recoveryMulticenter cohort analysisAcute lymphocytic leukemia patientsFavorable prognostic significanceLymphocytic leukemia patientsReal-world outcomesConsolidation therapyMRD negativityPrior therapyRelease syndromeComplete remission
2016
Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia
Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Annals Of Hematology 2016, 95: 1895-1898. PMID: 27468851, PMCID: PMC10955604, DOI: 10.1007/s00277-016-2761-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAged, 80 and overAntibodies, BispecificAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBone MarrowBreast NeoplasmsCarcinoma, Transitional CellCytarabineFemaleHumansLymphoma, B-CellMercaptopurineMethotrexateNeoplasms, Second PrimaryPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrednisoneRemission InductionSalvage TherapyUrinary Bladder NeoplasmsVincristine